Invention Grant
US09243294B2 Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
有权
NLGn4表达的调节，非酒精性脂肪性肝病（NAFLD）中的NK细胞活性
- Patent Title: Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
- Patent Title (中): NLGn4表达的调节，非酒精性脂肪性肝病（NAFLD）中的NK细胞活性
-
Application No.: US14501160Application Date: 2014-09-30
-
Publication No.: US09243294B2Publication Date: 2016-01-26
- Inventor: Rifaat Safadi
- Applicant: Rifaat Safadi
- Applicant Address: IL Jerusalem
- Assignee: Hadasit Medical Research Services and Development Ltd.
- Current Assignee: Hadasit Medical Research Services and Development Ltd.
- Current Assignee Address: IL Jerusalem
- Agency: Roach Brown McCarthy & Gruber, P.C.
- Agent Kevin D. McCarthy
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C07H21/02 ; C07H21/04 ; C12Q1/68 ; A61K31/7088 ; A61K45/06 ; C12N15/113 ; A61K31/713 ; A61K31/7105
Abstract:
The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NLGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
Public/Granted literature
- US20150094355A1 MODULATION OF NLGn4 EXPRESSION, NK CELL ACTIVITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) Public/Granted day:2015-04-02
Information query
